April 4, 2011
Treatment Of Barrett’s Esophagus May Lower Risk Of Esophageal Cancer
New guidelines support use of Radiofrequency Ablation to remove precancerous cells
New guidelines issued by the American Gastroenterological Association (AGA) support the use of radiofrequency ablation (RFA) to remove precancerous cells in patients with Barrett's esophagus, a condition most commonly caused by chronic acid reflux, or GERD. Barrett's esophagus is the leading cause of esophageal cancer and affects an estimated two million Americans. While traditionally managed through watchful waiting, experts at Northwestern Medicine's Center for Esophageal Disease have been among the pioneers of ablation treatment and have long seen the benefits of early treatment.
"The incidence of esophageal cancer is increasing more rapidly than any other type of cancer in the United States and survival rates remain low," said Northwestern Medicine gastroenterologist Srinadh Komanduri, MD. "Barrett's esophagus is a precancerous condition, and while the majority of people who suffer from the disorder will never develop cancer, the risk is present. Early treatment with RFA would likely reduce a patient's chance to develop cancer."
RFA burns away layers of abnormal cells and effectively eliminates the disease in 90-100 percent of patients. Doctors use a flexible tube (endoscopy) inserted into the esophagus to reach the treatment area, which also provides access for taking biopsies or endoscopic resection of suspicious lesions.
Northwestern's Center for Esophageal Disease is the top program in Chicago and has treated more than 130 patients with endoscopic therapy.
"We have seen great results using RFA therapy," said Komanduri who is also an assistant professor of medicine at Northwestern University Feinberg School of Medicine. "It effectively cures Barrett's esophagus in most patients, leads to fewer surgical procedures for the disease, and contributes to lowering the growth rate of esophageal cancer."
The new AGA guidelines recommend RFA treatment for patients with low to high grade dysplasia due to Barrett's esophagus and suggest it as an effective option for high-risk patients without dysplasia. Speak with your physician to determine if you are a candidate.
The Center for Esophageal Disease is operated by a multidisciplinary team of physicians and offers state-of-the-art diagnostics and treatment for patients with benign (non-cancerous) and malignant (cancerous) disorder of the esophagus. To make an appointment, please call 312-926-8400 or visit www.nmh.org.
On the Net: